Chen Jinbo, Cui Yu, Li Peng, Liu Longfei, Li Chao, Zu Xiongbing
Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Department of Pathology and Laboratory Medicine, The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14620, USA.
Mol Clin Oncol. 2017 Nov;7(5):919-927. doi: 10.3892/mco.2017.1389. Epub 2017 Aug 23.
Emerging evidence has demonstrated that androgen receptor (AR) is a promising therapeutic target for bladder cancer. However, the relationship between AR expression and its clinical significance remains controversial. The present in-depth meta-analysis aimed to investigate the correlation between AR expression and clinicopathological features, as well as prognostic value in bladder cancer. A systematic search was performed from PubMed, Web of Knowledge, Embase and the Cochrane Central Search Library by January 2017. The correlation between AR expression and tumor stage, tumor grade, recurrence free survival and progression free survival for patients with bladder cancer was evaluated. A total of 12 relevant studies with 1,652 patient samples were included. AR expression positively correlated with low tumor grade [odds ratio (OR), 1.95; 95% confidence interval (CI), 1.36-2.81], low tumor stage (OR, 2.06; 95% CI, 1.02-4.16) and low recurrence rate [hazard ratio (HR), 0.48; 95% CI, 0.31-0.75] in Caucasian patients. While, its expression had no significant impact on cancer susceptibility (OR, 1.62; 95% CI, 0.19-13.72; P=0.44) and progression-free survival (HR, 1.20; 95% CI, 0.86-1.66; P=0.77). The present meta-analysis indicated that AR expression correlates with tumor grade, clinical stage and recurrence rates in the specified population and classification system. Further studies are required to determine the precise role of AR in bladder cancer.
新出现的证据表明，雄激素受体（AR）是膀胱癌一个有前景的治疗靶点。然而，AR表达与其临床意义之间的关系仍存在争议。本项深入的荟萃分析旨在研究AR表达与临床病理特征之间的相关性，以及在膀胱癌中的预后价值。截至2017年1月，通过PubMed、Web of Knowledge、Embase和Cochrane Central Search Library进行了系统检索。评估了AR表达与膀胱癌患者肿瘤分期、肿瘤分级、无复发生存率和无进展生存率之间的相关性。共纳入12项相关研究，涉及1652例患者样本。在白种人患者中，AR表达与低肿瘤分级[比值比（OR），1.95；95%置信区间（CI），1.36 - 2.81]、低肿瘤分期（OR，2.06；95% CI，1.02 - 4.16）和低复发率[风险比（HR），0.48；95% CI，0.31 - 0.75]呈正相关。然而，其表达对癌症易感性（OR，1.62；95% CI，0.19 - 13.72；P = 0.44）和无进展生存率（HR，1.20；95% CI，0.86 - 1.66；P = 0.77）无显著影响。本荟萃分析表明，在特定人群和分类系统中，AR表达与肿瘤分级、临床分期和复发率相关。需要进一步研究以确定AR在膀胱癌中的精确作用。
